Serum CRP Levels and Response to IL-2 in Metastatic Renal Carcinoma
Author Information
Author(s): Jean-Yves Blay, Sylvie Negrier, Thierry Philip, Marie Favrot, Alain Mercatello
Primary Institution: Centre Leon Berard
Hypothesis
Is there an inverse correlation between pretreatment serum CRP levels and response to IL-2 in patients with metastatic renal carcinoma?
Conclusion
Higher pretreatment serum CRP levels are associated with a poorer response to IL-2 therapy in metastatic renal carcinoma patients.
Supporting Evidence
- Patients with progressive disease had significantly higher pretreatment CRP levels than those with stable or objective responses.
- Only 3% of patients with CRP over 50 mg achieved a response to IL-2 compared to 24% of those with lower CRP levels.
Takeaway
If patients have high levels of a protein called CRP before treatment, they are less likely to respond well to a cancer therapy called IL-2.
Methodology
Serum CRP levels were measured in patients before starting IL-2 therapy, and their responses were evaluated.
Participant Demographics
Patients with metastatic renal carcinoma treated with IL-2.
Statistical Information
P-Value
0.007
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website